院內感染市場規模、佔有率和成長分析（按類型、治療方法、感染類型、最終用戶和地區分類）—2026-2033年產業預測

預計到 2024 年，全球醫院感染市場規模將達到 308.6 億美元，到 2025 年將達到 313.2 億美元，到 2033 年將達到 352.8 億美元，預測期（2026-2033 年）的複合年成長率為 1.5%。

醫院感染市場的發展主要受微生物（如病毒、細菌、真菌和寄生蟲）傳播的驅動，這些微生物可導致多種感染疾病，包括呼吸系統疾病、消化器官系統和皮膚疾病。這些感染疾病的傳播通常透過病患、醫護人員和醫療設備之間的交叉感染發生。各種產品和服務，包括滅菌消毒液、防護屏障和內視鏡再處理工具，對於控制這些感染疾病至關重要。推動市場成長的因素包括：人們對醫院感染的認知不斷提高、降低交叉感染率的需求、感染疾病病例的增加以及政府為支持感染控制而採取的舉措。此外，嚴格的感染預防通訊協定的實施和先進監測技術的應用也顯著促進了市場擴張。

全球醫院感染市場促進因素

全球外科手術數量的不斷成長推動了對各種手術器械和醫療設備的需求。造成這一成長的因素包括肥胖率上升、文明病增加、人口老化以及脊柱和運動相關損傷的急劇增加。因此，隨著這些手術的日益普及，消毒器械和醫療設備的需求也隨之成長。人們對醫療環境中消毒和感染控制重要性的認知不斷提高，進一步推動了對醫院感染相關服務的需求。這一趨勢凸顯了在醫療機構中維持高衛生標準的重要性。

限制全球醫院感染控制市場的因素

可重複使用醫療設備的再處理雖然能為醫療機構帶來經濟效益並減少廢棄物，但也引發了人們對安全性和有效性的重大擔憂。例如，手術鉗、內視鏡和聽診器等器械，如果清潔和消毒不當，可能會殘留血液和組織，增加病患手術部位感染（SSI）的風險。這些生物殘留物的存在可能使有害微生物在後續消毒程序中存活下來，進而導致院內感染（HAI）。此外，再處理過程中殘留的化學物質會刺激組織，進一步增加患者照護的難度。因此，這些問題阻礙了醫院管理者和臨床醫師廣泛接受器械再處理的做法。

全球醫院感染市場趨勢

全球醫院感染控制市場正經歷顯著成長，其主要促進因素是環境污染和不健康的生活方式等因素導致糖尿病、心血管疾病和癌症等慢性疾病發生率不斷上升。隨著這些疾病盛行率的持續攀升，手術頻率預計也將增加，這必然會提高醫院感染的風險。因此，醫療機構對有效的感染控制設備和消毒方法的需求日益成長。這一趨勢凸顯了開發先進解決方案以減少感染傳播的必要性，最終推動了醫院感染控制產品和技術市場的發展。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球醫院感染市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 裝置
  • 消毒器
  • 消毒設備
• 消耗品
  • 消毒劑
  • 無菌耗材
  • 其他
• 服務

全球醫院感染市場規模（依治療方法及複合年成長率分類）（2026-2033 年）

• 抗菌劑
• 抗病毒藥物
• 抗真菌劑
• 其他

全球醫院感染市場規模（按感染疾病類型和複合年成長率分類）（2026-2033 年）

• 血液感染疾病
• 人工呼吸器相關性肺炎（VAP）
• 尿道感染
• 手術部位感染
• 胃腸道感染疾病
• 其他

全球醫院感染市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院和診所
• 門診手術中心
• 其他

全球醫院感染市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• STERIS plc（Ireland）
• Getinge AB（Sweden）
• 3M（USA）
• Ecolab Inc.（USA）
• Diversey Holdings, Ltd.（USA）
• Roche Holding AG（Switzerland）
• Abbott Laboratories（USA）
• bioMerieux SA（France）
• Thermo Fisher Scientific Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（UK）
• Sanofi SA（France）
• Medtronic plc（Ireland）
• Cardinal Health（USA）
• Johnson & Johnson（USA）

結論與建議

Global Hospital-Acquired Infections Market size was valued at USD 30.86 Billion in 2024 and is poised to grow from USD 31.32 Billion in 2025 to USD 35.28 Billion by 2033, growing at a CAGR of 1.5% during the forecast period (2026-2033).

The hospital-acquired infections market is driven by the prevalence of microorganisms, such as viruses, bacteria, fungi, and parasites, which can lead to numerous infections, including respiratory, gastrointestinal, and skin-related conditions. The transmission of these infections often occurs through cross-contamination from patients, healthcare staff, and medical equipment. A variety of products and services, including sterilization, disinfection solutions, protective barriers, and endoscope reprocessing tools, are crucial for managing these infections. Factors propelling market growth include heightened awareness of hospital-acquired infections, the imperative to minimize cross-infection rates, rising cases of infectious diseases, and government initiatives supporting infection control measures. Additionally, the adoption of stringent infection prevention protocols and the integration of advanced monitoring technologies contribute significantly to market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hospital-Acquired Infections market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hospital-Acquired Infections Market Segments Analysis

Global Hospital-Acquired Infections Market is segmented by Type, Treatment, Infection Type, End User and region. Based on Type, the market is segmented into Equipment, Consumables and Services. Based on Treatment, the market is segmented into Antibacterial, Antiviral, Antifungal and Others. Based on Infection Type, the market is segmented into Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection, Gastrointestinal Infections and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hospital-Acquired Infections Market

The rising prevalence of surgical procedures globally has led to an increased need for various surgical instruments and medical devices. Factors contributing to this rise include the growing rates of obesity, lifestyle-related illnesses, an aging demographic, and a surge in spine and sports-related injuries. Consequently, as these procedures become more common, the demand for sterilized equipment and medical devices intensifies. Enhanced awareness regarding the importance of sterilization and infection control in healthcare environments is further driving the demand for services related to hospital-acquired infections. This trend underscores the critical nature of maintaining high standards of hygiene in medical settings.

Restraints in the Global Hospital-Acquired Infections Market

The reprocessing of reusable medical devices presents both financial benefits and waste reduction for healthcare providers but also raises significant safety and efficacy concerns. Devices such as surgical forceps, endoscopes, and stethoscopes may harbor residual blood and tissue if not properly cleaned and sterilized, thereby elevating the risk of surgical site infections (SSIs) in patients. The presence of this biological debris can allow harmful microorganisms to survive through subsequent disinfection attempts, potentially resulting in hospital-acquired infections (HAIs). Additionally, residual chemicals from reprocessing can irritate tissue, further complicating patient care. Consequently, these issues hinder the widespread acceptance of reprocessing practices among hospital administrators and clinicians.

Market Trends of the Global Hospital-Acquired Infections Market

The Global Hospital-Acquired Infections market is experiencing significant growth driven by the rising incidence of chronic diseases such as diabetes, cardiovascular disorders, and cancer, largely attributed to factors like environmental pollution and unhealthy lifestyles. As the prevalence of these diseases continues to grow, the frequency of surgical procedures is also expected to increase, inevitably heightening the risk of hospital-acquired infections. Consequently, there is a greater demand for effective infection control devices and sterilization methods within healthcare facilities. This trend underscores the necessity for advanced solutions to mitigate infection transmission, ultimately propelling the market for hospital-acquired infection control products and technologies forward.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hospital-Acquired Infections Market Size by Type & CAGR (2026-2033)

• Market Overview
• Equipment
  • Sterilization Equipment
  • Disinfection Equipment
• Consumables
  • Disinfectants
  • Sterilization Consumables
  • Others
• Services

Global Hospital-Acquired Infections Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Antibacterial
• Antiviral
• Antifungal
• Others

Global Hospital-Acquired Infections Market Size by Infection Type & CAGR (2026-2033)

• Market Overview
• Bloodstream Infections
• Ventilator-Associated Pneumonia (VAP)
• Urinary Tract Infection
• Surgical-Site Infection
• Gastrointestinal Infections
• Others

Global Hospital-Acquired Infections Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Hospital-Acquired Infections Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Infection Type, End User)
  • US
  • Canada
• Europe (Type, Treatment, Infection Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Infection Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Infection Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Infection Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• STERIS plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ecolab Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diversey Holdings, Ltd. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations